Viela Bio Receives U.S. FDA Breakthrough Therapy Designation for Inebilizumab for Treatment of Neuromyelitis Optica Spectrum Disorder

Viela Bio
Published on : Published by : Chris Frew

Viela Bio Receives U.S. FDA Breakthrough Therapy Designation for Inebilizumab for Treatment of Neuromyelitis Optica Spectrum Disorder Designation based on positive primary analysis of pivotal study, N-MOmentum Gaithersburg, MD—April 18, 2019 – Viela Bio today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the Company’s anti-CD19 monoclonal antibody [….]

BioHealth Capital Region is Entering Period of “Creative Destruction” at Perfect Time

Published on : Published by : Steven Surdez

BioHealth Capital Region is Entering Period of “Creative Destruction” at Perfect Time March 12, 2019 In 1942, Austrian economist Joseph Schumpeter wrote, “ …industrial mutation—if I may use that biological term—that incessantly revolutionizes the economic structure from within, incessantly destroying the old one, incessantly creating a new one. This process of Creative Destruction is the [….]

Viela Bio’s Spinout Story Reveals A Roadmap for Growth Ahead

Published on : Published by : Chris Frew

Viela Bio’s Spinout Story Reveals A Roadmap for Growth Ahead November 6, 2018 In order: Elizabeth Parsons (Member, Mintz Levin), Aaron Ren (Head of BD and Operations, Viela Bio), Christian Dinneen-Long (Senior Council, AstraZeneca), and Chris Jeffers (Member, Mintz Levin), participate in panel discussion at TEDCO’s Entrepreneur Expo on the Viela Bio Corporate Spinout Story [….]